BioSapien

By 2030 deaths from pancreatic cancer are expected to exceed colorectal, breast, and prostate cancer, trailing only lung cancer and making it the second leading cause of cancer-related death in the US. Unlike other common cancers of the preceding decades, pancreatic cancer has seen little to no improvement in outcomes; rapid progression, difficult surgery, and resistance to systemic chemotherapy have continued to thwart attempts to improve treatment. BioSapien's solution is the Medichip, a implantable, biodegradable, drug-eluting mesh targeting several treatment-resistant features of pancreatic cancer by delivering high-concentration chemotherapy to unresectable structures (i.e. major vasculature) and poorly perfused, fibrotic, tumor tissues which have thus-far dramatically limited the success of surgery and chemotherapy. Interested in learning more? If so, our CEO Khatija A. would love to hear from you! #innovation #cancer #STEM #3Dprinting #biosapien #bioali #biosalem #BSPN

What a way to wrap up ADFW 2024 🚀 The final day celebrated innovation, collaboration, and the incredible Hub71 community, closing the week with impactful moments and promising connections. Here’s to building the future of FinTech together ✨ #Hub71 #ADFW2024 #TechEcosystem ADGM | David Wernery - Terrax | Flo Akinbiyi | Zain Tarawneh - Hub71 | Khatija A. - BioSapien | LP (Louis-Philippe) Noel - BioTwin | Lorena P. - syd™ | Talal Hasan - 44.01 | Rick Fox - Partanna | Sonia Weymuller - VentureSouq | Paul Mahacek - AtmoCooling | Deniz Tekerek - Archireef

Exciting news! 🚀 BioSapien, a cutting-edge biotech company focused on localized drug delivery, has successfully raised $5.5 million in pre-Series A funding! Their flagship product, MediChip™, is a 3D-printed, slow-release drug delivery platform designed to treat cancer locally, minimizing systemic side effects while increasing drug efficacy. This innovative technology has the potential to revolutionize cancer treatment, providing patients with better quality of life, fewer side effects, and reducing the need for invasive surgeries. With this new funding, BioSapien will accelerate its clinical trials in the UAE, beginning patient enrolment in Abu Dhabi in Q2 2025. The company is also focused on expanding product development, manufacturing, and talent acquisition to further enhance their life-changing platform. We are proud to support BioSapien in their mission to redefine cancer treatment, and look forward to the impact this groundbreaking technology will have on patients in the UAE and beyond! Congratulations Khatija A.! Read more here: https://lnkd.in/d4iARU6f

We at BioSapien are proud to announce that we have raised over $5.5M for our pre-A financing. Congrats to the team! More hard work to be done and results to follow. Stay tuned!

BioSapien’s CEO, Khatija A., receives the 2024 Most Influential CEO Award in Biotech USA! 🏆 BioSapien is leading the charge in cancer treatment innovation with its cutting-edge product, MediChip—a drug delivery platform to treat tumours directly with chemotherapy, minimising debilitating side effects. This recognition highlights the significant impact BioSapien is making in the biotech industry, driving forward its mission to transform cancer treatment and improve patients' quality of life. As the biotech landscape continues to evolve, innovations like MediChip are crucial in offering more effective, patient-friendly solutions. Learn more about this achievement and BioSapien’s journey: https://biosapien.com/